Program
Rituximab
Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.
Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.
Drug pageRituximab: every studyMany companies study it; this page follows only the 124 they lead. All 1,284 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 781 open or running | phase 4since Jan 18, 2007 | Apr 1, 2003 | none ahead |
| SymBio Pharmaceuticalsits history only | 50 open or running | phase 3since Dec 10, 2017 | Nov 18, 2008 | none ahead |
| AbbVieits history only | 40 open or running | phase 3since Jun 9, 2014 | Apr 20, 2012 | none ahead |
| AstraZenecaits history only | 42 open or running | phase 4since Aug 23, 2023 | Apr 8, 2016 | Oct 31, 2028phase 2 · NCT05951959 |
| Biogenits history only | 40 open or running | phase 4since Aug 23, 2004 | Mar 31, 2003 | none ahead |
| Takedaits history only | 40 open or running | phase 3since Apr 7, 2006 | Jun 11, 2004 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| Celltrionits history only | 30 open or running | phase 1since Feb 8, 2012 | Feb 8, 2012 | none ahead |
| Favrilleits history only | 30 open or running | phase 3since Aug 4, 2004 | Aug 4, 2004 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 3since Oct 13, 2017 | Dec 14, 2015 | none ahead |
| ImmunityBioits history only | 22 open or running | phase 1since Oct 19, 2022 | Oct 19, 2022 | Oct 2027phase 1 · NCT06334991 |
| Mabionits history only | 20 open or running | phase 3since Jun 9, 2015 | Jun 9, 2015 | none ahead |
| Merckits history only | 20 open or running | phase 1since May 18, 2011 | May 18, 2011 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Bayerits history only | 10 open or running | phase 2since Jul 8, 2004 | Jul 8, 2004 | none ahead |
| Mabscaleits history only | 11 open or running | phase 1since Dec 7, 2023 | Dec 7, 2023 | none ahead |
| Pharmatechits history only | 10 open or running | phase 2since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| Probiomed S.A. de C.V.its history only | 10 open or running | phase 3since Jan 8, 2011 | Jan 8, 2011 | none ahead |
| Sinocelltech Groupits history only | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
Also a collaborator on its studies: ICON Clinical Research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, Roche Pharma and Chiron.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 7, 2011.
- Oct 13, 2017Phase 3 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT03312907 · 292 enrolled · United States, Argentina, Brazil and more
- Dec 10, 2017Phase 3 study in Lymphoma, Large B-Cell, DiffuseSymBio Pharmaceuticals · NCT03372837 · 40 enrolled · Japan
- Mar 6, 2019Phase 2 study in LymphomaSymBio Pharmaceuticals · NCT03900377 · 37 enrolled · Japan
- Jul 22, 2019Phase 1 study in Multiple MyelomaHoffmann-La Roche · NCT04045028 · 41 enrolled · United States, Korea, Republic of
- Nov 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04660799 · 50 enrolled · China
- Jan 13, 2021Phase 3 study in RecurrenceHoffmann-La Roche · NCT04712097 · 478 enrolled · United States, Australia, Brazil and more
- Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04790903 · 50 enrolled · United States, France, Italy and more
- May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT05364424 · 43 enrolled · United States
- Oct 19, 2022ImmunityBio’s first study: phase 1 study in RecurrenceNew to ImmunityBioImmunityBio · NCT05618925 · 20 planned · United States
- Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959 · 108 enrolled · United States, Australia, Brazil and more
- Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
- Aug 23, 2023Phase 4 study in HypophosphatasiaAstraZeneca · NCT06015750
- Dec 7, 2023Mabscale’s first study: phase 1 study in Arthritis, RheumatoidNew to MabscaleMabscale · NCT06175338 · 208 enrolled · Russian Federation
- Mar 5, 2024Phase 1 study in Non-Hodgkin Lymphoma Refractory/ RelapsedImmunityBio · NCT06334991 · 20 enrolled · South Africa
- Jan 29, 2026Named rituximabINNProposed as its International Nonproprietary Name in WHO's List 134 · before, MK-8808
Ahead
- Oct 2027Primary completion: phase 1 study in Non-Hodgkin Lymphoma Refractory/ RelapsedImmunityBio · NCT06334991
- Oct 31, 2028Primary completion: phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959
- Apr 22, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024
TargetBeta
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06334991Non-Hodgkin Lymphoma Refractory/ Relapsed · South Africa | 1 | Active, not recruiting | ImmunityBio | Oct 2027 | 20 |
| NCT06175338Arthritis, Rheumatoid · Russian Federation | 1 | Active, not recruiting | Mabscale | Nov 2024 | 208 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more | 2 | Recruiting | AstraZeneca | Apr 22, 2029 | 80 |
| NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Oct 31, 2028 | 108 |
| NCT05618925Recurrence · United States | 1 | Recruiting | ImmunityBio | May 15, 2026 | 20 |
| NCT05364424Lymphoma, Large B-Cell, Diffuse · United States | 1 | Completed | Hoffmann-La Roche | Oct 15, 2025 | 43 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | Hoffmann-La Roche | May 21, 2024 | 50 |
| NCT04712097Recurrence · United States, Australia, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 3, 2026 | 478 |
| NCT04660799Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Hoffmann-La Roche | May 23, 2022 | 50 |
| NCT04045028Multiple Myeloma · United States, Korea, Republic of | 1 | Terminated | Hoffmann-La Roche | Mar 28, 2023 | 41 |
| NCT03900377Lymphoma · Japan | 2 | Completed | SymBio Pharmaceuticals | Sep 9, 2020 | 37 |
| NCT03372837Lymphoma, Large B-Cell, Diffuse · Japan | 3 | Completed | SymBio Pharmaceuticals | Dec 31, 2019 | 40 |
| NCT03312907Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Completed | GlaxoSmithKline | May 29, 2020 | 292 |
| NCT02735876Lymphoma, Mantle-Cell | 3 | Withdrawn | AstraZeneca | Jun 2020 | 0 |
| NCT02744196Arthritis, Rheumatoid | 3 | Completed | Biocad | Feb 2017 | 159 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Aug 2002 | 161 |
| NCT02631538Sjogren's Syndrome · Argentina, Canada, France and more | 2 | Completed | GlaxoSmithKline | Jun 23, 2020 | 86 |
| NCT02617485Lymphoma, Large B-Cell, Diffuse · Bosnia and Herzegovina, Croatia, Georgia and more | 3 | Completed | Mabion | Aug 2017 | 143 |
| NCT02600897Recurrence · United States, Spain, United Kingdom | 2 | Completed | Hoffmann-La Roche | Dec 15, 2021 | 114 |
| NCT02569996Lymphoma, Follicular · Hungary | 3 | Completed | Hoffmann-La Roche | Aug 2013 | 124 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Hoffmann-La Roche | Dec 2014 | 34 |
| NCT02468791Arthritis, Rheumatoid · Bosnia and Herzegovina, Georgia, Poland and more | 3 | Completed | Mabion | May 2017 | 709 |
| NCT02406092Lymphoma, Non-Hodgkin · Algeria, Morocco, Tunisia | 3 | Completed | Hoffmann-La Roche | Jun 30, 2021 | 139 |
| NCT02383589Pemphigus · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Nov 28, 2018 | 135 |
| NCT02257567Lymphoma · United States, Australia, Canada and more | 2 | Completed | Hoffmann-La Roche | Oct 21, 2021 | 331 |
| NCT02206308Lymphoma, B-Cell | 1 | Completed | Sinocelltech Group | Jul 2013 | 15 |
| NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 3 | Completed | AbbVie | Nov 7, 2019 | 181 |
| NCT02115997Granulomatosis with Polyangiitis · India | 4 | Completed | Hoffmann-La Roche | Jun 7, 2022 | 30 |
| NCT02097745Arthritis, Rheumatoid · United States, Belgium, Canada and more | 3 | Completed | Hoffmann-La Roche | Jun 2013 | 341 |
| NCT02093026Arthritis, Rheumatoid · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Dec 2012 | 465 |
| NCT02079532Arthritis, Rheumatoid · Germany | 3 | Completed | Hoffmann-La Roche | Nov 2010 | 302 |
| NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more | 2 | Completed | AbbVie | Dec 17, 2020 | 138 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Hoffmann-La Roche | Jun 28, 2017 | 267 |
| NCT02006706Arthritis, Rheumatoid · Serbia | 3 | Completed | Hoffmann-La Roche | Nov 23, 2007 | 15 |
| NCT02013817Leukemia, Lymphocytic, Chronic, B-Cell · Austria | 2 | Completed | Hoffmann-La Roche | Sep 24, 2012 | 43 |
| NCT01998893Lymphoma, Non-Hodgkin · Germany | 2 | Completed | Hoffmann-La Roche | Feb 2008 | 38 |
| NCT01987505Lymphoma, Non-Hodgkin · Spain | 3 | Completed | Hoffmann-La Roche | Apr 11, 2017 | 140 |
| NCT01980654Lymphoma, Follicular · United States | 2 | Completed | AbbVie | Nov 2017 | 80 |
| NCT01889069Lymphoma · Italy | 3 | Completed | Hoffmann-La Roche | May 28, 2019 | 159 |
| NCT01873443Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Oct 2014 | 87 |
| NCT01759030Arthritis, Rheumatoid · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Jul 2015 | 181 |
| NCT01750697Granulomatosis with Polyangiitis · United States, Canada, France and more | 2 | Completed | Hoffmann-La Roche | May 10, 2018 | 25 |
| NCT01724021Lymphoma, Large B-Cell, Diffuse · Argentina, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Jan 2015 | 743 |
| NCT01718691Low-grade B Cell Non-Hodgkin's Lymphoma · Japan | 2 | Completed | SymBio Pharmaceuticals | Nov 2013 | 70 |
| NCT01701232Lymphoma, Follicular · Colombia, India, Russian Federation and more | 3 | Completed | Biocad | Jan 2017 | 174 |
| NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany | 1 | Completed | Hoffmann-La Roche | Aug 17, 2018 | 84 |
| NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more | 3 | Completed | Hoffmann-La Roche | Oct 21, 2014 | 572 |
| NCT01594229Lymphoma, Non-Hodgkin · United States | 1 | Completed | AbbVie | Jul 14, 2020 | 60 |
| NCT01534949Lymphoma, Large B-Cell, Diffuse · Korea, Republic of | 1 | Terminated | Celltrion | Feb 2013 | 1 |
| NCT01534884Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Aug 2013 | 154 |
| NCT01461928Lymphoma, Non-Hodgkin · Albania, Argentina, Austria and more | 3 | Completed | Hoffmann-La Roche | Jun 2, 2018 | 692 |
| NCT01397825Lymphoma, Large B-Cell, Diffuse · United States, Italy, Spain and more | 2 | Completed | Takeda | Feb 5, 2015 | 45 |
| NCT01390441Arthritis, Rheumatoid | 1 | Terminated | Merck | Apr 2014 | 100 |
| NCT01392716Lymphoma, Non-Hodgkin · France | 2 | Completed | Hoffmann-La Roche | Feb 2006 | 48 |
| NCT01388959Lymphoma, Non-Hodgkin · France | 2 | Completed | Hoffmann-La Roche | Apr 2004 | 40 |
| NCT01382940Arthritis, Rheumatoid · United States | 4 | Completed | Hoffmann-La Roche | Jan 6, 2013 | 351 |
| NCT01370694Lymphoma, Follicular | 1 | Terminated | Merck | Dec 1, 2014 | 7 |
| NCT01277172Lymphoma, Large B-Cell, Diffuse · Mexico | 3 | UNKNOWN | Probiomed S.A. de C.V. | Sep 2011 | 54 |
| NCT01272908Arthritis, Rheumatoid · Canada, Sweden | 3 | Completed | Hoffmann-La Roche | Mar 12, 2009 | 120 |
How it is read
Names in the registry
- “Rituximab”, 104 entries
- “rituximab”, 34 entries
- “rituximab [MabThera/Rituxan]”, 23 entries
- “Rituximab SC”, 2 entries
- “MK-8808”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 34 studies
- Lymphoma, Non-Hodgkin, 33 studies
- Lymphoma, Large B-Cell, Diffuse, 23 studies
- Lymphoma, Follicular, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.